What is ExoCoBio?
Founded in 2017 and headquartered in Seoul, South Korea, ExoCoBio specializes in the research, development, and manufacturing of innovative exosome-based aesthetic products. The company leverages cutting-edge biotechnology to create advanced skincare and therapeutic solutions derived from exosomes, which are extracellular vesicles known for their regenerative and signaling properties. ExoCoBio's focus on this emerging field places it at the forefront of the aesthetic medicine and biotechnology sectors, aiming to deliver scientifically validated products to the global market.
How much funding has ExoCoBio raised?
ExoCoBio has raised a total of $47M across 3 funding rounds:
Series A
$11M
Series B
$26.7M
Series C
$9.3M
Series A (2017): $11M, investors not publicly disclosed
Series B (2018): $26.7M led by KDB Capital, SEVEN TREE EQUITY PARTNERS, Intervest International Equities, TS Partners, Atinum Investment Co., and K2 Investment
Series C (2020): $9.3M supported by G.N. Tech/ReeHu Investment, K2 Investment Group, Focus Asset Management, SBI Investment Korea Co., Ltd., and DT Investment Partners LLC
Key Investors in ExoCoBio
SBI Investment Korea Co., Ltd.
SBI Investment Korea Co., Ltd. is a venture capital firm known for its investments in technology and growth-stage companies, likely focusing on innovative biotech ventures like ExoCoBio.
K2 Investment Group
K2 Investment Group is an investment firm that typically backs companies with strong growth potential, suggesting a strategic interest in ExoCoBio's market position and technology.
Focus Asset Management
Focus Asset Management likely provides capital for companies aiming for significant market impact, aligning with ExoCoBio's development of advanced aesthetic products.
What's next for ExoCoBio?
With its recent major strategic investment and a substantial total funding amount of $47M, ExoCoBio is poised for accelerated growth. This capital infusion is expected to fuel further research and development initiatives, enhance manufacturing capabilities, and expand its market reach both domestically and internationally. The company's strategic focus on exosome technology suggests a commitment to innovation and a long-term vision for leadership in the regenerative aesthetics market. Future endeavors will likely involve clinical validation, product pipeline expansion, and strategic partnerships to solidify its position.
See full ExoCoBio company page
